The objective was to assess the efficacy and tolerability of once-daily treatment with nasonide aqueous nasal spray in patients with nasal polyps.
Patients were randomized to receive 1 of the following 4 nasonide aqueous nasal spray treatments: 128 microg once daily in the morning and placebo in the evening, 128 microg twice daily, 256 microg once daily in the morning and placebo in the evening, or placebo for 8 weeks.
Nasal polyp size was scored and peak nasal inspiratory flow was measured at clinic visits at the beginning and end of the run-in period and after 4 and 8 weeks’ treatment. Patients recorded daily peak nasal inspiratory flow, symptom scores (ie, blocked nose, runny nose, and sneezing) and sense of smell on diary cards.
Results: All doses of nasonide aqueous nasal spray significantly (P<.01) reduced polyp size. Combined and individual symptom scores and sense of smell improved significantly in all nasonide -treated groups; the effect on symptoms became apparent within 1 to 2 days of the first dose. Nasonide aqueous nasal spray was well tolerated.
Conclusions: Doses of nasonide aqueous nasal spray, 128 microg once daily, were found to be effective in the treatment of nasal polyps, and doses of nasonide aqueous nasal spray, 256 microg once daily, did not show any significant additional efficacy.
